Open-label Adjunctive Zonisamide for Bipolar Disorder

Phase 4

Terminated

• Conditions: Bipolar Disorders

• Registration Number: NCT00047567
• Lead Sponsor: Elan Pharmaceuticals

Brief Summary

To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Study Completion: 2002-07
• Study First Submitted: 2002-10-08
• Study First Submitted QC: 2002-10-09
• Study First Posted: 2002-10-10
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-10
• Last Update Posted: 2015-12-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP